--Research and develop a therapeutic for control of hemorage on the battlefield as well as in management of hospital surgeries and trauma cases.

The U.S. Army Research Development and Engineering Command Contracting Center, Natick Contracting Division, supporting the Naval Health Research Center in San Diego, intends to award a Firm Fixed Price contract to Entegrion, Inc. for the research and development of a therapeutic infusible hemostatic agent aimed at controlling hemorrhage both on the battlefield and in hospital surgeries and trauma cases. This contract is a continuation of a three-year ongoing effort and involves proprietary, exclusively licensed U.S. patented technologies that uniquely qualify Entegrion to perform the required clinical trials and research. The procurement is being made under sole-source authority due to the specialized nature of the technology and prior work, and this posting serves only as a notification of intent to negotiate with Entegrion rather than a solicitation or request for proposals. The contract will be managed under the NAICS code 541711, with the office located in Natick, Massachusetts. The announcement was posted on November 24, 2008, and the notification period will remain open for 15 days. Inquiries related to the acquisition must be submitted exclusively via email to the designated point of contact, with no telephone inquiries accepted. This approach reinforces the unique position of Entegrion to continue research supporting battlefield trauma care and hospital emergency use, emphasizing the critical nature of the therapeutic being developed and the exclusivity of the licensed technology involved.